** Shares of drugmaker Bristol Myers Squibb BMY.N fall 3.9% to $57.39 premarket
** Co forecasts 2025 revenue of around $45.5 billion, below analysts' average expectation of $47.4 billion - LSEG data
** Sees 2025 EPS between $6.55 and $6.85 per share, below estimates of $6.92
** BMY expects generic competition for some of its older drugs
** Co is expanding its cost-cutting program by additional $2 billion by end of 2027, bringing total cost cuts under the program to $3.5 billion
** Stock rose ~10% in 2024
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。